A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: procedure (650), etiquette (1), practice (609)

Bevacizumab (15mgkg), Carboplatin and Gemcitabine (1,8)

Description
Chemotherapy Protocol GYNAECOLOGICAL CANCER BEVACIZUMAB (15)-CARBOPLATIN (AUC4)-GEMCITABINE (day 1, 8) Regimen • Ovary-Bevacizumab (15)-Carboplatin (AUC4)-Gemcitabine (1, 8
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/Bevacizumab15mgkgCarboplatinAUC4Gemcitabineday18.pdf

Rituximab-Gemcitabine-Oxaliplatin (R-GemOx)

Description
Chemotherapy Protocol LYMPHOMA RITUXIMAB-GEMCITABINE-OXALIPLATIN (R-GemOx) Regimen • Lymphoma – Rituximab-Gemcitabine-Oxaliplatin (R-GemOx) Indication • Salvage regimen for relapsed/refractory
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-Gemcitabine-Oxaliplatin-R-GemOx.pdf

Capecitabine-Trastuzumab-SC-Tucatinib

Description
Chemotherapy Protocol BREAST CANCER Capecitabine– Trastuzumab (SC)-Tucatinib Regimen • Breast Cancer – Capecitabine–Trastuzumab (SC)-Tucatinib Indication • Treatment of over-expressed HER2
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Capecitabine-Trastuzumab-SC-Tucatinib.pdf

Inotuzumab Ozogamicin

Description
Relapsed or refractory CD22-positive B-Cell acute lymphoblastic leukaemia.
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/ALL/Inotuzumab-Ozogamicin.pdf

Papers Council of Governors 20 July 2022

Description
Agenda attachments 1 CoG Agenda - 20.07.2022.docx Date Time Location Chair Agenda Council of Governors 20/07/2022 14:00 - 15:30 Micro
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2022-Trust-documents/Papers-Council-of-Governors-20-July-2022.pdf

Endometrial-Dostarlimab

Description
Chemotherapy Protocol GYNACOLOGICAL CANCER Dostarlimab Regimen  Endometrial - Dostarlimab Indication  Dostarlimab is indicated for patients with; - proven histological diagnosis of endometrial carcinoma
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Uterine-cancer/Dostarlimab.pdf

Durvalumab_14day

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Durvalumab (14 day) Regimen • NSCLC - Durvalumab (14 day) Indication • Stage 3 NSCLC after
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Durvalumab-14day.pdf

Durvalumab(28day-1500mg)

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Durvalumab (28 day – 1500mg) Regimen • NSCLC - Durvalumab (28 day – 1500mg) Indication • Durvalumab is
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Durvalumab28day-1500mg.pdf

InP-Bleomycin-Cisplatin-Etoposide (5 day BEP) Ver1.2

Description
Chemotherapy Protocol GERM CELL BLEOMYCIN-CISPLATIN-ETOPOSIDE (BEP 5 Day) In-Patient Regimen Regimen Germ Cell – InP-Bleomycin-Cisplatin-Etoposide (5
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Germcell/InP-Bleomycin-Cisplatin-Etoposide-5-day-BEP-Ver1.2.pdf

Bleomycin-Cisplatin-Etoposide (3 day BEP) Ver1.2

Description
Chemotherapy Protocol GERM CELL BLEOMYCIN-CISPLATIN-ETOPOSIDE (BEP 3 Day) Regimen Germ Cell – Bleomycin-Cisplatin-Etoposide (3 day BEP) Indication In
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Germcell/Bleomycin-Cisplatin-Etoposide-3-day-BEP-Ver1.2.pdf
551 to 560 of 698
Previous … 54 55 56 57 58 … Next